# Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy

> **NCT02903368** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 118 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Apalutamide
- **DRUG:** Leuprolide
- **DRUG:** Prednisone
- **DRUG:** Abiraterone Acetate

## Key facts

- **NCT ID:** NCT02903368
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-19
- **Primary completion:** 2022-04-05
- **Final completion:** 2024-07-10
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2025-06-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02903368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02903368, "Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02903368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*